Product Information
LATISSE 0.03% EYELASH SOLUTION is a brand product labeled by Allergan, Inc., priced at $31.4906 per ML under NDC 00023361605. Its NADAC has been published 338 times since Aug 22, 2018.
FDA first approved this application on Dec 24, 2008. Its Orange Book therapeutic-equivalence code is AT.
The High Outlier badge above means this manufacturer's average price in the bimatoprost market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.3 mg/mL
Manufacturer
Allergan, Inc.NDC
00023361605
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BIMATOPROSTApproval Type
New Drug (NDA)
FDA Application
NDA022369FDA Approved
12/24/2008
TE Code
AT
On Market Since
1/26/2009
Pharmacological Classes
Price Statistics
The NADAC for LATISSE 0.03% EYELASH SOLUTION has been published 338 times since Aug 22, 2018, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $31.4906 per ML |
|---|---|
| All-time high | $31.6764 (Feb 12, 2020) |
| All-time low | $31.4314 (Jun 17, 2026) |
| 52-week high | $31.5339 |
| 52-week low | $31.4314 |
| Median price | $31.4946 |
| Average price | $31.5348 |
| Largest weekly change | -0.7% (Feb 19, 2020) |
| Weeks tracked | 338 |
| Tracking since | Aug 22, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bimatoprost market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Prostaglandin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LATISSE 0.03% EYELASH SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for LATISSE 0.03% EYELASH SOLUTION, manufactured by Allergan, Inc., is $31.4906 per ML (NDC 00023361605), effective Sep 30, 2026.
How has the price of LATISSE 0.03% EYELASH SOLUTION changed over time?
Over the history we have for it, the NADAC for LATISSE 0.03% EYELASH SOLUTION has held within roughly two percent of its current level. It has been tracked across 338 weekly CMS publications since Aug 22, 2018.
What are the highest and lowest recorded NADAC prices for LATISSE 0.03% EYELASH SOLUTION?
Since Aug 22, 2018, the NADAC for LATISSE 0.03% EYELASH SOLUTION has ranged from a low of $31.4314 (Jun 17, 2026) to a high of $31.6764 (Feb 12, 2020), with a median of $31.4946 per ML.
Are there cheaper alternatives to LATISSE 0.03% EYELASH SOLUTION?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BIMATOPROST 0.03% EYELASH SOLN, is $20.6493 per ML — about 34% below LATISSE 0.03% EYELASH SOLUTION.
Who manufactures LATISSE 0.03% EYELASH SOLUTION?
LATISSE 0.03% EYELASH SOLUTION (NDC 00023361605) is labeled by Allergan, Inc., and CMS classifies it as a brand product.